Patent Expiries of Insulin in 2014 to Drive the Growth of Biosimilars
The patents of some of the major rapid acting insulin analogs are set to expire in 2014. This surge of patent expiries is set to create opportunities for biosimilar players such as Biocon and Wockhardt. In fact, global players such as Sanofi are also banking on the launch of next generation insulin to counteract the loss from patent expiration from biologic molecules. The pipeline for insulin biosimilars is dominated by Biocon and Wockhardt. Wockhardt’s Lispro is in Phase III whereas...
View full press release